The dominant principle in the practice of transplantation infectious disease is that infection and rejection are inextricably intertwined, linked by the immunosuppressive therapy required to maintain allograft function. Any intervention that decreases the risk of infection, thus permitting more intensive immunosuppressive therapy, will increase the rate of allograft survival without threatening the patient's survival; conversely, any intervention that decreases the need for immunosuppressive therapy will lower the risk and consequences of infection without threatening the survival of the allograft. Thus, the therapeutic prescription for a transplant patient has two components: the immunosuppressive program and an antimicrobial strategy to render the immunosuppressive therapy safe (45) .
There are three different modes in which antimicrobial drugs can be used: a therapeutic mode, in which antimicrobial agents are administered to treat established disease; a prophylactic mode, in which nontoxic antimicrobial agents are administered to all individuals to prevent an infection that is both common enough and important enough to merit such an approach; and a preemptive mode, in which antimicrobial agents are administered to a subgroup of patients prior to the appearance of clinical disease. The last mode is predicated on the use of a laboratory marker or patient characteristic that identifies that subgroup of individuals with the highest risk of serious disease at a time when antimicrobial intervention would be maximally effective in aborting the disease process (44) .
Because the consequences of infection can be so devastating in transplant patients, the emphasis of this minireview (as it is in clinical practice) is on the prophylactic and preemptive strategies that can be used to prevent clinical infection. ORGAN TRANSPIANT RECIPIENT The most important single infection in transplant recipients is that caused by cytomegalovirus (CMV), which not only is directly responsible for a variety of infectious disease syndromes (fever, pneumonia, hepatitis, gastrointestinal ulcerations, etc.) but also contributes significantly to the patient's net state of immunosuppression and may be involved in the pathogenesis of allograft injury (43 4 months posttransplantation (26, 43, 49) .
ANTIMICROBMIL STRATEGIES AGAINST VIRAL INFECTION IN THE
Given the protean manifestations of CMV infection in the transplant patient, great attention has been devoted to the treatment and prevention of this infection. Ganciclovir by itself has been shown to have significant benefit in the treatment of clinical CMV disease, particularly in patients without CMV pneumonia, severe gastrointestinal disease, or prolonged leukopenia (8, 12, 13, 26, 31, 42, 43) . Studies in a murine model of CMV (46) and bone marrow transplant recipients with CMV pneumonia (14, 40) (1, 10, 26, 29, 37, 41, 54) .
A variety of prophylactic programs that use high-dose acyclovir administered orally (2, 4, 17, 63) , both CMV hyperimmune (33, 49, 50) and standard immunoglobulin (51, 52) , and the combination of these two approaches (36, 53) , as well as ganciclovir (3, 32) , have been studied for the prevention of the different patterns of CMV transmission in patients undergoing the various types of organ transplantation (Table  1) . Although the data base is quite incomplete because of (i) High-dose acyclovir administered orally, as well as hyperimmune globulin (and perhaps standard immunoglobulin), administered singly or in combination over a period of 4 months has considerable efficacy in decreasing the incidence of primary CMV disease in renal transplant patients being immunosuppressed with cyclosporine, prednisone, and azathioprine. However, there is significantly less efficacy when antilymphocyte antibody therapies (e.g., antithymocyte globulin, antilymphocyte serum, or OKT3) are added to the immunosuppressive programs for these patients. Unfortunately, there is little evidence that any of these prophylactic programs, or even ganciclovir administered for 1 month posttransplantation, has any effect on the occurrence of primary CMV disease following heart, lung, or liver transplantation (2-4, 17, 32, 33, 36, 49-53) .
(ii) Prevention of CMV disease in seropositive allograft recipients (at risk for either reactivation or superinfection disease) appears to be possible with any of these regimens, particularly when antilymphocyte antibody therapies are not used (2, 4, 17, 32, 33, 36, (49) (50) (51) (52) (53) .
(iii) Definition of the optimal doses and the duration of each of these prophylactic programs has not yet been accomplished. In the case of acyclovir, prophylactic efficacy occurs when peak levels in blood are approximately 25 ,umol/liter, in the face of an average 50% inhibitory concentration of approximately 45 pLmol/liter (2, 4, 17) , suggesting that inhibition of the virus is most easily accomplished as it emerges from latency and when only small amounts of replicating virus are present. In the case of intravenous immunoglobulin therapy, the nature of the protecting antibody, its epitopic specificity, and the titers necessary to protect the individual are currently unknown. Thus, it is not surprising that the relative merits of standard intravenous globulin and a preparation hyperimmune for anti-CMV antibodies, or their optimal doses, are currently unknown. Despite these unknowns, it is remarkable that even partial protection has been achieved with these prophylactic regimens. These issues will become even more important as monoclonal anti-CMV antibodies are developed. Studies in the murine model (15) , as well as those defining the nature of circulating antibody in seropositive humans (7) , have clearly shown that in vitro anti-CMV neutralizing activity does not necessarily confer protection.
(iv) With any of these prophylactic programs, it is clear that the addition of antilymphocyte antibody therapy-the immunosuppressing agents with the greatest ability to reactivate latent virus-to the antirejection regimen attenuates the efficacy of the prophylactic effort. Recently, Hibberd et al. (22, 24) have reported that the addition of antilymphocyte antibody therapy to standard cyclosporine-based immunosuppressive programs in seropositive renal allograft recipients increased the incidence of CMV disease five-fold. When ganciclovir was administered preemptively for the duration of the antilymphocyte antibody treatment (usually 10 to 14 days), the incidence of clinical disease fell from >50% to the baseline value of approximately 15%. In this instance, the antimicrobial strategy was tailored to meet the special challenge posed by the intensive immunosuppressive therapy required. We have found this approach to be equally effective in recipients of heart, liver, and lung allografts (24) .
In sum, considerable progress has been made in both the treatment and, even more important, the prevention of CMV disease. Although this is an area of great flux at present, we speculate that the most effective anti-CMV strategy that emerges will have the following features: a basic prophylactic program given to all patients at risk for CMV disease; the prophylactic program will probably combine low doses of both an antiviral agent such as acyclovir or ganciclovir with low doses of an immunoglobulin preparation; in addition, preemptive therapy with ganciclovir will be added at times of optimal stress-during periods of intensive immunosuppression (as in the studies of Hibberd et al. [22, 24] (21, 23, 25, 45) . Treatment of such patients with high-dose trimethoprim-sulfamethoxazole or intravenous pentamidine is effective in more than 80% of individuals, but it is associated with a high rate of side effects. The most important of these side effects is severe nephrotoxicity caused by interactions with cyclosporine (see below) and bone marrow inhibition (45) . In contrast, low-dose trimethoprim-sulfamethoxazole (e.g., 80 mg of trimethoprim plus 400 mg of sulfamethoxazole once daily) is both highly effective in preventing Pneumocystis pneumonia and is largely free of the toxic side effects that complicate full-dose therapeutic programs (23, 30, 45) . In those patients who are unable to tolerate low-dose trimethoprim-sulfamethoxazole prophylaxis, alternative regimens such as monthly aerosolized or parenteral pentamidine (and, presumably, other regimens such as dapsone that are effective in patients with AIDS) are substituted. The exact duration of time that such prophylaxis should be continued is unclear. Since more than 80% of the cases of P. carinii infection occur in the first 6 months posttransplantation, our policy has been to prescribe prophylaxis for 6 months in renal transplant patients. This is continued for an additional 6 months in the extrarenal transplant patients and is reinstituted any time that the patient's level of immunosuppression is going to be increased for more than a few days (45) .
In the special case of the heart transplant patient who is seronegative for toxoplasmosis prior to transplantation and receives an allograft from a toxoplasmosis-seropositive donor (and thus is at high risk for disseminated toxoplasmosis), pyrimethamine and sulfadiazine provide effective prophylaxis against both P. carinii and toxoplasmosis. Although there are scattered reports of toxoplasmosis in noncardiac organ transplant recipients, the incidence appears to be so low that routine antitoxoplasmosis prophylaxis for these patients does not appear to be indicated (16, 20, 27, 45) . S. stercoralis can cause life-threatening hyperinfestation syndromes or disseminated infection with accompanying gram-negative sepsis and/or meningitis in the transplant patient years after the individual acquired asymptomatic infection in areas endemic for S. stercoralis (e.g., much of the developing world). Whereas eradication of infection pretransplantation with thiobendazole is relatively easy, treatment of the life-threatening infections posttransplantation is difficult. Hence, examination of purged stool or small bowel samples from individuals with histories of exposure to this infectious agent is appropriate pretransplantation. Alternatively, preemptive therapy in anyone with an appropriate epidemiologic history is not unreasonable, particularly given the difficulties in diagnosing S. stercoralis infection (16, 35, 45) .
ANTIMICROBUIL STRATEGIES AGAINST BACTERUIL INFECTION IN THE ORGAN
TRANSPLANT RECIPIENT Both low-dose trimethoprim-sulfamethoxazole and lowdose ciprofloxacin have clearly been shown to provide significant protection against the development of urinary tract infections in renal transplant recipients (18, 23, 57) . In the case of trimethoprim-sulfamethoxazole, additional protection is also provided against clinical infections with such organisms as Listeria monocytogenes, Nocardia asteroides, and perhaps other bacterial pathogens, as well as the previously discussed P. carini (45) . Again, a 6-to 12-month period of prophylaxis posttransplantation appears to be adequate for preventing the majority of such infections.
Perioperative antibacterial administration has been shown to be effective in preventing wound infections in renal transplant recipients (45, 56, 58) . In this instance, such therapy should be aimed at uropathogens and staphylococci. Such regimens as cefazolin, cefamandole, or ampicillinsulbactam administered on an on-call basis in the operating room and continuing for less than 24 h posttransplantation have been quite effective (e.g., at our hospital, a wound infection rate of <0.2% has been observed over the past 10 years). Although no comparable controlled studies have been performed in patients undergoing extrarenal organ transplantation, perioperative prophylaxis has become standard practice. The general principles to be applied here, we believe, are the following. Eradicate the active infection prior to transplantation, perioperative prophylaxis should begin on an on-call basis in the operating room and should continue for less than 3 days posttransplantation, and the antibiotics chosen should be designed to cover staphylococci and the resident flora of the transplanted site (e.g., gramnegative organisms and, possibly, Candida species in the case of liver transplantation). In the case of lung transplant candidates, our practice has been to monitor their sputum cultures at least twice monthly prior to transplantation and then to individualize the prophylactic regimen to reflect the resident flora in the individual whose lung is being transplanted (45) . VOL. 37, 1993 Liver transplantation, of all the forms of organ transplantation, has been associated with the highest rate of lifethreatening bacterial and candidal infections, with major infections reported in as many as 79% of liver transplant patients. Most such infections are located intra-abdominally and are due to such factors as surgical manipulation of the bowel and biliary tree at the time of liver transplantation, devitalization of remaining tissues, intraperitoneal hemorrhage perioperatively, and the need for reexploration (6, 11, 38, 45, 60) . Adapting the selective bowel decontamination approach used in cancer chemotherapy patients, a number of groups administer a variety of nonabsorbable antibacterial agents (e.g., gentamicin and polymyxin B combined with nystatin or amphotericin B) orally to eradicate the aerobic gram-negative flora while leaving the anaerobic flora, which confers colonization resistance, intact (34, 38, 59, 62 (38, 45, 61, 62) . In addition, some groups have advocated the use of a short (<2-week) course of intravenous amphotericin peritransplantation (34) .
(ii) Preemptive therapy of asymptomatic candiduria is indicated, particularly in diabetic renal transplant patients. Because of toxicity issues, our current preference is for 2 weeks of fluconazole or low-dose (10 mg/day) amphotericin B plus flucytosine to accomplish this task (45) .
(iii) Preemptive therapy of transplant patients whose respiratory tracts, either upper or lower, are colonized with Aspergillus species appears to be warranted. This appears to be particularly important in patients with cystic fibrosis who are ready to receive either a lung or a liver transplant. Whether amphotericin B or itraconazole is best suited for this task and the role that aerosolized amphotericin B can play here remains to be determined (45) .
GENERAL PRINCIPLES OF ANTIMICROBIAL TREATMENT OF ESTABLISHED INFECTION IN ORGAN TRANSPLANT RECIPIENTS
Thus far in this minireview, preventive strategies have been stressed. An important reason for this is the potential toxicities of full-dose antimicrobial treatment regimens in patients receiving cyclosporine-based immunosuppressive regimens (the current standard of care in organ transplantation). Three types of interactions commonly occur between cyclosporine and a variety of antimicrobial agents. Certain drugs (most notably rifampin) upregulate the metabolism of cyclosporine by the critical hepatic cytochrome P-450 enzyme system, thus decreasing the levels of cyclosporine in blood and the immunosuppressing effect of cyclosporine and potentially leading to allograft rejection. Other drugs (most notably erythromycin and presumably the newer macrolides ketoconazole, itraconazole, and, to a lesser extent, fluconazole) downregulate the hepatic metabolism of cyclosporine, leading to higher levels of the drug in blood, and the potential for both cyclosporine toxicity and overimmunosuppression (some groups have advocated the routine administration of these antimicrobial agents to take advantage of this effect by lowering the dose and cost of cyclosporine required). Finally, there is non-dose-related, presumably idiosyncratic, synergistic nephrotoxicity. This last interaction is the one that is of primary concern, because the first two interactions can be dealt with by monitoring cyclosporine levels in blood and making appropriate dosage adjustments. Synergistic nephrotoxicity has been observed with an ever increasing list of antimicrobial compounds, most notably amphotericin B, aminoglycosides,'vancomycin, high therapeutic doses of trimethoprim-sulfamethoxazole, pentamidine, and itraconazole. In general, antimicrobial therapy should emphasize the use of extended-spectrum beta-lactam molecules, quinolones (even here, higher doses may be of concern, because we have observed toxicity with doses of ciprofloxacin of >800 mg/day in transplant patients with normal renal function), and fluconazole. However, the general rule remains that when unexplained deterioration in renal function occurs in transplant patients, possible antimicrobial interactions with cyclosporine must be considered (45, 47 
